The use of multiple medications is associated with increased severity of erectile dysfunction, according to a Kaiser Permanente study published online in the British Journal of Urology International. This study surveyed 37,712 ethnically diverse men from Southern California and found that men taking various medications are likely to have more severe ED...
Spanish researchers have uncovered clear links between erectile dysfunction (ED) and peripheral neuropathy, according to a paper in the December issue of the urology journal BJUI...
The more medications a man is on, the higher is his risk of developing erectile dysfunction, also known as impotence, researchers from Kaiser Permanente reported in the British Journal of Urology International. Not only is the risk of ED (erectile dysfunction) greater, but also the condition's severity. Lead author, Diana C. Londoño, MD...
A study published on bmj.com shows that male bowel cancer patients have a high probability of suffering from erectile dysfunction (ED) after their treatment yet in spite of this, the majority of patients does not receive sufficient information about the condition...
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Cialis® (tadalafil) tablets for once daily use for the treatment of men who have both erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (ED+BPH)...
Tadalafil (Cialis) has been approved by the FDA (Food and Drug Administration) for the treatment of BPH (benign prostatic hyperplasia) signs and symptoms - a condition in which the prostate gland enlarges. It has also been approved for the treatment of simultaneous BPH and ED (erectile dysfunction). Since 2003, the medication has been on the market legally in the USA for ED treatment...
More than two-thirds of men who contacted an email advice service run by a leading sexual advice charity had erection problems, which were frequently linked to loss of sex drive, according to research in the October issue of IJCP, the International Journal of Clinical Practice...
A study published in the Sept. 21 issue of the Journal of the American Medical Association by a Beth Israel Deaconess Medical Center research team, suggests more open discussion between doctor and patient will assist in improving quality of life for prostate cancer survivors...
VIVUS, Inc. (NASDAQ: VVUS) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's new drug application (NDA) for its investigational drug candidate, avanafil, for the treatment of erectile dysfunction (ED). The target date for the FDA to complete its review of the avanafil NDA is April 29, 2012...
For men with erectile dysfunction (ED), 65 percent are unable to have an orgasm and 58 percent have problems with ejaculation, according to new research led by physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The study followed 12,130 men with mild to severe ED and is the largest-ever analysis of orgasmic and ejaculatory dysfunction...
